Nephrogenic Systemic Fibrosis: History and Epidemiology

Radiologic Clinics of North America

Volumn 47, Issue 5, 2009, Pages 827-831

  Thomsen, Henrik S ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adverse reactions; Epidemiology; Gadolinium based contrast media; Nephrogenic systemic fibrosis; Prevalence

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOTEXETATE SODIUM; GADOVERSETAMIDE; HEAVY METAL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANAPHYLAXIS; DRUG EXPOSURE; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; MEDICAL DOCUMENTATION; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; REVIEW;

CONTRAST MEDIA; GADOLINIUM DTPA; HISTORY, 20TH CENTURY; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PREVALENCE;

EID: 69649105921     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2009.05.003     Document Type: Review

References (36)

1. Nelson K.L., and Runge V.M. Basic principles of MR contrast. Top Magn Reson Imaging 7 (1995) 124-136
2. De Haën C. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 12 (2001) 221-230
3. Wastie M.L., and Latief K.H. Gadolinium: named after Finland's most famous chemist. Br J Radiol 77 (2004) 146-147
4. Greenen R.W.F., and Krestin G.P. Non-tissue specific extracellular MR contrast media. In: Thomsen H.S. (Ed). Contrast media. Safety issues and ESUR guidelines (2006), Springer, Heidelberg 107-114
5. Dawson P. Gadolinium chelates: chemistry. In: Dawson P., Cosgrove D.O., and Grainger R.G. (Eds). Textbook of contrast media (1999), Isis Medical Media, Oxford 291-296
6. Desreux J.F., and Gilsoul D. Chemical synthesis of paramagnetic complexes. In: Thomsen H.S., Muller R.N., and Mattrey (Eds). Trends in contrast media (1999), Springer Verlag, Heidelberg 161-169
7. Morcos S.K. Extracellular gadolinium contrast agents (Gd-CA): differences in stability. Eur J Radiol 66 (2008) 175-179
8. Idee J.-M., Port M., Raynal I., et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
9. Sherry A.D., Cacheris W.P., and Kuan K.-T. Stability constants for Gd3+ binding to model DTPA-conjugates and DTPA-proteins: implications for their use as magnetic resonance contrast agents. Magn Reson Med 8 (1988) 180-190
10. Caravan P., Ellison J.J., McMurry T.J., et al. Gadolinium (III) chelates and MRI agents: structure, dynamics and applications. Chem Rev 99 (1999) 2293-2352
11. Hammer F.D., Gofette P.P., Malaise J., et al. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 9 (1999) 128-136
12. Spinosa D.J., Matsumoto A.H., Hagspiel K.D., et al. Gadolinium-based contrast agents in angiography and interventional radiology. AJR Am J Roentgenol 173 (1999) 1403-1409
13. Gemmete J.J., Fortauer A.R., Kazanjian S., et al. Safety of large volume gadolinium angiography. [abstract]. J Vasc Interv Radiol 12 part 2 (2001) S28
14. Marzaellla L., Blank M., Gelperin K., et al. Safety risks with gadolinium-based contrast agents. [letter]. J Magn Reson Imaging 26 (2007) 816
15. Van der Molen A.J. Diagnostic efficacy. In: Thomsen H.S., and Webb J.A.W. (Eds). Contrast media: safety issues and ESUR guidelines (2009), Springer Verlag, Heidelberg 161-169
16. Heinz-Peer G. Acute adverse reactions. In: Thomsen H.S., and Webb J.A.W. (Eds). Contrast media: safety issues and ESUR guidelines (2009), Springer Verlag, Heidelberg 181-184
17. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
18. Cowper S.E., Su L.D., Bhawan J., et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383-393
19. Marckmann P., Skov L., Rossen K., et al. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 69 (2008) 161-168
20. Todd D.J., Kagan A., Chibnik L.B., et al. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56 (2007) 3433-3441
21. Swaminathan S., High W.A., Ranville, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73 (2009) 1413-1418
22. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
23. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
24. Thomsen H.S., Marckmann P., and Logager V.B. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 16 (2008) 551-560
25. Cowper S.E., Rabach M., and Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66 (2008) 200-207
26. Grebe S.O., Borrman M., Altenburg A., et al. Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. Clin Exp Nephrol 12 (2008) 403-406
27. Thomsen H.S. Is NSF only the tip of the "gadolinium toxicity" iceberg?. J Magn Reson Imaging 28 (2008) 284-286
28. Broome D.R. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 6 (2008) 230-234
29. Deng A., Bilu Martin D., Spillane J., et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol (2009) Epub
30. Thomsen H.S., and Marckmann P. Extracellular Gd-CA: differences in prevalences of NSF. Eur J Radiol 66 (2008) 180-183
31. Rydahl C., Thomsen H.S., and Marckman P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium(Gd)-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141-144
32. Wertman R., Altun E., Martin D.R., et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248 (2008) 799-806
33. Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol 66 (2008) 187-190
34. Thomsen H.S., Marckmann P., and Logager V.B. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?. Acta Radiol 48 (2007) 593-596
35. Cowper S.E. Nephrogenic systemic fibrosis. Adv Dermatol 23 (2007) 131-154
36. Stenver D.I. Pharmacovigilance: what to do if you see an adverse reaction and the consequences. Eur J Radiol 66 (2008) 184-186